• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Assay Power

  2026-04-28

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) delivers unmatched dual-modality detection for real-time tracking and quantification in mRNA delivery and expression studies. Its Cap1 capping, 5-moUTP modification, and Cy5 fluorescent labeling streamline advanced workflows, suppress innate immune activation, and yield robust, reproducible data across imaging and reporter assays.

• Structural Basis of HCAR3 Agonist Selectivity in Lipid Metab

  2026-04-27

  The reference study provides high-resolution cryo-EM structures of HCAR3 in complex with selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran). These insights clarify the molecular determinants of ligand recognition and selectivity, informing next-generation hypolipidemic agent design with reduced side effects.

• Morin: Bioactive Flavonoid for Mitochondrial and Probe Appli

  2026-04-27

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a high-purity flavonoid used in biomedical research for its antioxidant, anti-inflammatory, and fluorescent chelation properties. Its unique ability to inhibit adenosine 5′-monophosphate deaminase and act as an aluminum ion probe supports disease modeling in diabetes, neurodegeneration, and more.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Pr

  2026-04-26

  DiI (DiIC18(3)) enables robust, high-contrast plasma membrane labeling in live and fixed cells, supporting applications like neuronal tracing and cell migration assays. This probe should not be used in water-based protocols or for targeting intracellular organelles. Researchers benefit most when requiring detailed membrane visualization with organic-solvent workflows.

• Peptidisc-Driven Nanobody Multimers: Enabling New Protein As

  2026-04-25

  This study introduces a peptidisc-assisted strategy to cluster nanobodies into multimeric and multispecific assemblies, termed polybodies, enhancing their affinity and functional versatility. The approach leverages hydrophobic clustering stabilized by peptidisc membrane mimetics and demonstrates potential for expanding protein engineering capabilities in biochemical research.

• Sulfo-NHS-SS-Biotin: Precision Protein Labeling for Affinity

  2026-04-24

  Sulfo-NHS-SS-Biotin empowers selective, reversible protein labeling, making it an indispensable tool for affinity purification and bioconjugation of cell surface proteins. Its cleavable disulfide linker and high aqueous solubility streamline workflows for cell biology and proteomics, as validated by both recent literature and robust product data.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-24

  Schwartz's dissertation reveals significant differences between relative and fractional viability metrics in in vitro drug response assays, highlighting how these measures capture distinct aspects of cancer cell fate. This work provides a framework to better interpret anti-cancer drug efficacy and suggests that more nuanced evaluation methods can refine preclinical testing and translational research.

• Cy5-UTP for RNA Labeling: Applied Workflows & Troubleshootin

  2026-04-23

  Cy5-UTP (Cyanine 5-UTP) empowers researchers with direct, sensitive fluorescent RNA labeling in complex workflows. Discover optimized in vitro protocols, troubleshooting strategies, and how lipid nanoparticle innovations inform next-generation probe design.

• Moxifloxacin: Fluoroquinolone Antibiotic for Cellular Toxici

  2026-04-23

  Moxifloxacin stands out as a broad-spectrum fluoroquinolone antibiotic, enabling precise exploration of DNA replication inhibition, cytotoxicity, and metabolic shifts in mammalian and bacterial cells. This guide details actionable experimental workflows, troubleshooting strategies, and differentiating insights—anchored by recent mechanistic advances and APExBIO’s rigorous product standards.

• Decitabine Enhances Anti–PD-1 Efficacy via CD8+ Progenitor T

  2026-04-22

  This study demonstrates that low-dose Decitabine priming potentiates anti–PD-1 immunotherapy by promoting the expansion and functional capacity of CD8+ progenitor exhausted T cells within tumor models. These findings provide mechanistic insight into how epigenetic modulation can overcome limitations of immune checkpoint blockade and inform future combination strategies in cancer epigenetics.

• Hexa-acylated LPS in Gut Microbiota Boosts Cancer Immunother

  2026-04-22

  This study reveals that gut microbiota-derived hexa-acylated lipopolysaccharides (LPS) enhance the efficacy of immune checkpoint inhibitor (ICI) therapy in cancer. By linking specific LPS structures, rather than just taxonomic composition, to improved anti-tumor immune responses, the research advances understanding of microbiome-immune interactions and informs future approaches to immunotherapy.

• Applied Cancer Research with Anti-ROR1 Antibody (Zilovertama

  2026-04-21

  Unlock precise Wnt5a-induced ROR1 signaling inhibition with Anti-ROR1 Antibody (Zilovertamab) for robust ELISA, FACS, and animal model workflows. This APExBIO reagent empowers advanced anti-tumor research with actionable protocols, troubleshooting, and data-driven optimizations.

• Phage-Layer Interferometry: Advancing Phage Therapy Diagnost

  2026-04-21

  This article examines the development of Phage-Layer Interferometry (PLI) as a robust, quantitative diagnostic platform for bacteriophage therapy selection and bacterial detection. PLI overcomes key limitations of traditional phage screening, enabling high-throughput, automated assays even in complex and opaque biological samples.

• TG003 Cdc2-like kinase inhibitor: Precision in Splicing Rese

  2026-04-20

  TG003 stands out as a potent and selective Cdc2-like kinase inhibitor, empowering researchers to modulate alternative splicing and dissect platinum resistance mechanisms. Its reproducible performance streamlines workflows in cancer and neuromuscular disease models, delivering reliable pathway control for advanced translational studies.

• Proliferation Tracing Reveals Mechanisms of Breast Tumor Rel

  2026-04-20

  This study introduces a dual recombinase-based mouse model enabling precise tracing and ablation of proliferating cells in spontaneous breast cancer, emulating clinical relapse dynamics. By integrating single-cell transcriptomics, it uncovers how dormant, therapy-resistant cell populations and microenvironmental changes drive tumor recurrence—offering a robust platform for evaluating anti-relapse interventions.

10313 records 7/688 page Previous Next First page 上5页 678910 下5页 Last page